Inhaled Amikacin to Prevent Ventilator-Associated Pneumonia.
Stephan EhrmannFrançois BarbierJulien DemiselleJean-Pierre QuenotJean-Etienne HerbrechtDamien RouxJean-Claude LacheradeMickaël LandaisPhilippe SeguinDavid SchnellAnne VeinsteinPhilippe GouinSigismond LasockiQin LuGaëtan BeduneauMartine FerrandiereGaëtan PlantefèveClaire Dahyot-FizelierNader ChebibEmmanuelle MercierNathalie Heuzé-Vourc'hRenaud RespaudNicolas GregoireDenis GarotMai-Anh NayFerhat MezianiPascal AndreuRaphaël Clere-JehlNoémie ZucmanMarie-Ange AzaïsMarjorie Saint-MartinCharlotte Salmon GandonnièreDalila BenzekriHamid MerdjiElsa Taverniernull nullPublished in: The New England journal of medicine (2023)
Among patients who had undergone mechanical ventilation for at least 3 days, a subsequent 3-day course of inhaled amikacin reduced the burden of ventilator-associated pneumonia during 28 days of follow-up. (Funded by the French Ministry of Health; AMIKINHAL ClinicalTrials.gov number, NCT03149640; EUDRA Clinical Trials number, 2016-001054-17.).